What is HC Wainwright’s Forecast for Femasys Q3 Earnings?

Femasys Inc. (NASDAQ:FEMY) – Equities researchers at HC Wainwright raised their Q3 2025 earnings per share estimates for Femasys in a research note issued on Monday, August 11th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($0.12) for the quarter, up from their previous estimate of ($0.14). HC Wainwright currently has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Femasys’ current full-year earnings is ($0.86) per share. HC Wainwright also issued estimates for Femasys’ FY2025 earnings at ($0.59) EPS, FY2026 earnings at ($0.53) EPS, FY2027 earnings at ($0.41) EPS, FY2028 earnings at ($0.29) EPS and FY2029 earnings at ($0.13) EPS.

Separately, Jones Trading cut their price target on shares of Femasys from $10.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, May 13th.

Femasys Price Performance

NASDAQ:FEMY opened at $0.71 on Thursday. Femasys has a one year low of $0.69 and a one year high of $1.80. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.54 and a current ratio of 0.89. The stock has a market cap of $23.14 million, a PE ratio of -0.83 and a beta of -2.58. The stock has a 50 day moving average price of $0.89 and a 200 day moving average price of $1.13.

Femasys (NASDAQ:FEMY) last posted its quarterly earnings results on Friday, August 8th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.02. Femasys had a negative return on equity of 713.74% and a negative net margin of 1,113.72%. The firm had revenue of $0.41 million during the quarter, compared to analysts’ expectations of $0.80 million.

Institutional Trading of Femasys

A number of hedge funds and other institutional investors have recently made changes to their positions in FEMY. Dauntless Investment Group LLC purchased a new position in shares of Femasys during the 1st quarter worth approximately $1,969,000. Jane Street Group LLC purchased a new position in shares of Femasys during the 2nd quarter worth approximately $82,000. Citadel Advisors LLC purchased a new position in shares of Femasys during the 4th quarter worth approximately $45,000. Northern Trust Corp boosted its position in shares of Femasys by 42.6% during the 4th quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock worth $139,000 after purchasing an additional 37,675 shares during the period. Finally, Clear Creek Financial Management LLC boosted its position in shares of Femasys by 5.5% during the 1st quarter. Clear Creek Financial Management LLC now owns 270,371 shares of the company’s stock worth $338,000 after purchasing an additional 14,000 shares during the period. Institutional investors and hedge funds own 65.27% of the company’s stock.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.